Affordable_JJ CD4+-T-Cell_NN Counting_VBG by_IN Flow_NP Cytometry_NP :_: CD45_NP Gating_NP for_IN Volumetric_NP Analysis_NP The_DT flow_NN cytometers_NNS that_WDT are_VBP currently_RB supported_VBN by_IN industry_NN provide_VBP accurate_JJ CD4+-T-cell_NN counts_NNS for_IN monitoring_VBG human_JJ immunodeficiency_NN virus_NN disease_NN but_CC remain_VB unaffordable_JJ for_IN routine_JJ service_NN work_NN under_IN resource-poor_JJ conditions_NNS ._SENT We_PP therefore_RB combined_VBD volumetric_JJ flow_NN cytometry_NN (_( measuring_VBG absolute_JJ lymphocyte_NN counts_NNS in_IN unit_NN volumes_NNS of_IN blood_NN )_) and_CC simpler_JJR protocols_NNS with_IN generic_JJ monoclonal_NN antibodies_NNS (_( MAbs_NP )_) to_TO increase_VB cost_NN efficiency_NN ._SENT Volumetric_JJ absolute_JJ counts_NNS were_VBD generated_VBN using_VBG CD45/CD4_NP and_CC CD45/CD8_NP MAb_NP combinations_NNS in_IN two_CD parallel_JJ tubes_NNS ._SENT The_DT percentage_NN values_VBZ for_IN the_DT various_JJ subsets_NNS were_VBD also_RB determined_VBN within_IN the_DT leukocyte_NN and_CC lymphocyte_NN populations_NNS utilizing_VBG a_DT fully_RB automated_JJ protocol_NN ._SENT The_DT levels_NNS of_IN agreement_NN between_IN the_DT newly_RB developed_VBN method_NN and_CC the_DT present_JJ industry_NN standards_NNS ,_, including_VBG both_DT volumetric_JJ and_CC bead-based_JJ systems_NNS using_VBG a_DT full_JJ MAb_NP panel_NN for_IN subset_NN analysis_NN ,_, were_VBD tested_VBN by_IN Bland-Altman_NP analyses_NNS ._SENT The_DT limits_NNS of_IN agreement_NN for_IN CD4_NP counts_NNS generated_VBN by_IN the_DT volumetric_JJ methods_NNS using_VBG either_DT CD45/CD4_NP (_( in_IN a_DT single_JJ tube_NN )_) or_CC the_DT full_JJ Trio_NP MAb_NP panel_NN (_( in_IN three_CD tubes_NNS )_) on_IN the_DT CytoronAbsolute_JJ flow_NN cytometer_NN were_VBD between_IN -29_CD and_CC +46_JJ cells/mm3_NN with_IN very_RB little_JJ bias_NN for_IN CD4_NP counts_NNS (_( in_IN favor_NN of_IN the_DT Trio_NP method_NN :_: +8_NP CD4+_NP lymphocytes/mm3_NN ;_: 0.38_CD %_NN of_IN lymphocytes_NNS )_) ._SENT The_DT limits_NNS of_IN agreement_NN for_IN absolute_JJ CD4_NP counts_NNS yielded_VBD by_IN the_DT volumetric_JJ CD45/CD4_NP method_NN and_CC the_DT bead-based_JJ method_NN were_VBD between_IN -118_CD and_CC +98_JJ cells/mm3_NN ,_, again_RB with_IN a_DT negligible_JJ bias_NN (_( -10_CD CD4+_NP lymphocytes/mm3_NN )_) ._SENT In_IN the_DT volumetric_JJ method_NN using_VBG CD45/CD8_NP ,_, the_DT strongly_RB CD8+_JJ cells_NNS were_VBD gated_VBN and_CC the_DT levels_NNS of_IN agreement_NN with_IN the_DT full_JJ Trio_NP showed_VBD a_DT minor_JJ bias_NN (_( in_IN favor_NN of_IN the_DT Trio_NP ;_: +40_NP CD8+_NP cells/mm3_NN ;_: 5.2_CD %_NN of_IN lymphocytes_NNS )_) without_IN a_DT significant_JJ influence_NN on_IN CD4/CD8_NP ratios_NNS ._SENT One_CD trained_JJ flow_NN cytometrist_NN was_VBD able_JJ to_TO process_VB 300_CD to_TO 400_CD stained_VBN tubes_NNS per_IN day_NN ._SENT This_DT workload_NN extrapolates_VBZ to_TO a_DT throughput_NN of_IN >30,000_JJ samples_NNS per_IN year_NN if_IN both_DT CD45/CD4_NP and_CC CD45/CD8_NP stainings_NNS are_VBP performed_VBN for_IN each_DT patient_NN or_CC a_DT throughput_NN of_IN >60,000_JJ samples_NNS if_IN only_JJ CD45/CD4_NP counts_NNS are_VBP tested_VBN in_IN a_DT single_JJ tube_NN ._SENT Thus_RB ,_, on_IN the_DT basis_NN of_IN the_DT high_JJ efficiency_NN and_CC excellent_JJ agreement_NN with_IN the_DT present_JJ industry_NN standards_NNS ,_, volumetric_JJ flow_NN cytometers_NNS with_IN automated_JJ gating_VBG protocols_NNS and_CC autobiosamplers_NNS ,_, complemented_VBN by_IN generic_JJ CD45_NP ,_, CD4_NP ,_, and_CC CD8_NP MAbs_NP used_VBD in_IN two-color_NN immunofluorescence_NN ,_, represent_VBP the_DT most_RBS suitable_JJ arrangements_NNS for_IN large_JJ regional_JJ laboratories_NNS in_IN resource-poor_JJ settings_NNS ._SENT Dedicated_JJ flow_NN cytometers_NNS are_VBP designed_VBN to_TO enumerate_VB the_DT absolute_JJ numbers_NNS and_CC percentages_NNS of_IN lymphocyte_NN populations_NNS ,_, such_JJ as_IN subsets_NNS of_IN T_NN cells_NNS ,_, B_NP cells_NNS ,_, and_CC NK_JJ cells_NNS ._SENT In_IN the_DT clinical_JJ service_NN for_IN monitoring_VBG human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) disease_NN ,_, the_DT primary_JJ aim_NN is_VBZ to_TO deliver_VB absolute_JJ CD4+-T-cell_NN counts_NNS ,_, and_CC this_DT is_VBZ achieved_VBN with_IN a_DT remarkably_RB high_JJ level_NN of_IN precision_NN ._SENT Nevertheless_RB ,_, the_DT various_JJ cytometric_JJ systems_NNS differ_VBP in_IN complexity_NN ._SENT It_PP has_VBZ recently_RB been_VBN documented_VBN that_IN routine_JJ CD4-T-cell_NN enumeration_NN can_MD be_VB simplified_VBN without_IN compromising_VBG quality_NN ,_, leading_VBG to_TO cost-effective_JJ services_NNS for_IN patients_NNS who_WP receive_VBP generic_JJ antiretroviral_JJ drugs_NNS in_IN resource-poor_JJ settings_NNS ._SENT Among_IN the_DT flow_NN cytometers_NNS ,_, dedicated_JJ instruments_NNS operating_VBG as_IN "_`` single_JJ platforms_NNS "_`` are_VBP preferred_JJ due_RB to_TO their_PP$ convenience_NN and_CC accuracy_NN ._SENT These_DT single_JJ platforms_NNS are_VBP based_VBN either_RB on_IN a_DT volumetric_JJ principle_NN by_IN counting_VBG CD4+_NP T_NN cells_NNS in_IN a_DT unit_NN volume_NN of_IN blood_NN or_CC on_IN the_DT concept_NN of_IN adding_VBG known_VBN numbers_NNS of_IN fluorospheres_NNS ,_, or_CC "_`` microbeads_NNS ,_, "_'' to_TO each_DT sample_NN ._SENT These_DT beads_NNS are_VBP ,_, however_RB ,_, precision_NN products_NNS that_WDT can_MD increase_VB running_VBG costs_NNS ._SENT Consequently_RB ,_, services_NNS handling_VBG large_JJ numbers_NNS of_IN samples_NNS had_VBD to_TO revert_VB to_TO "_`` double_VB platforms_NNS "_`` operating_VBG a_DT panleucogating_VBG strategy_NN with_IN CD45_NP monoclonal_NN antibody_NN (_( MAb_NP )_) to_TO secure_VB a_DT much_RB less_RBR expensive_JJ but_CC still_RB accurate_JJ mode_NN of_IN operation_NN ._SENT Indeed_RB ,_, the_DT CD45-based_JJ gating_VBG ,_, an_DT example_NN of_IN the_DT "_`` heterogeneous_JJ "_'' gating_VBG strategy_NN ,_, is_VBZ a_DT more_RBR reliable_JJ protocol_NN when_WRB used_VBN with_IN autogating_VBG in_IN aging_VBG samples_NNS than_IN the_DT conventional_JJ gating_VBG strategies_NNS that_WDT utilize_VBP morphological_JJ scatter_NN gates_NNS ._SENT Despite_IN the_DT present_JJ interest_NN in_IN improving_VBG the_DT efficacy_NN of_IN routine_JJ flow_NN cytometry_NN ,_, the_DT performance_NN of_IN volumetric_JJ flow_NN cytometric_JJ systems_NNS operating_VBG with_IN CD45-based_JJ gating_VBG and_CC generic_JJ MAbs_NNS has_VBZ not_RB yet_RB been_VBN assessed_VBN ._SENT We_PP have_VBP therefore_RB investigated_VBN the_DT following_VBG topics_NNS :_: (_( i_NP )_) the_DT agreement_NN between_IN the_DT results_NNS of_IN CD45/CD4_NP staining_VBG using_VBG simple_JJ panleucogating_NN on_IN volumetric_JJ single_JJ platforms_NNS and_CC those_DT obtained_VBN on_IN the_DT full_JJ volumetric_JJ and_CC bead-based_JJ systems_NNS during_IN CD4+-T-cell_NN enumeration_NN ,_, including_VBG both_DT absolute_JJ counts_NNS and_CC CD4_JJ percentage_NN values_NNS (_( among_IN leukocytes_NNS and_CC lymphocytes_NNS )_) ;_: (_( ii_NP )_) the_DT increased_VBN sample_NN throughput_NN using_VBG CD45/CD4_NP staining_VBG ;_: (_( iii_NP )_) the_DT extension_NN of_IN this_DT protocol_NN to_TO include_VB a_DT second_JJ tube_NN for_IN CD45/CD8_NP staining_VBG in_IN order_NN to_TO obtain_VB CD4-plus-CD8_NP counts_NNS and_CC CD4/CD8_JJ ratios_NNS ;_: and_CC finally_RB ,_, (_( iv_NP )_) the_DT use_NN of_IN volumetric_JJ CD45_NP staining_VBG for_IN generating_VBG absolute_JJ and_CC differential_JJ counts_NNS for_IN leukocyte_NN subsets_NNS ._SENT Our_PP$ study_NN reveals_VBZ the_DT practical_JJ advantages_NNS of_IN volumetric_JJ two-color_JJ flow_NN cytometry_NN with_IN CD45/CD4_NP and_CC CD45/CD8_NP staining_VBG using_VBG generic_JJ MAbs_NNS ._SENT Volumetric_JJ cytometers_NNS ,_, equipped_VBN with_IN biosamplers_NNS of_IN high_JJ capacity_NN ,_, Microsoft_NP Windows-based_JJ autogating_NN software_NN ,_, and_CC reporting_VBG systems_NNS ,_, efficiently_RB handle_VB 300_CD to_TO 400_CD samples_NNS during_IN a_DT working_VBG day_NN ._SENT As_RB many_JJ as_IN 15_CD parameters_NNS ,_, including_VBG CD4_NP and_CC CD8_NP analysis_NN together_RB with_IN hematological_JJ leukocyte_NN differentials_NNS ,_, can_MD be_VB generated_VBN for_IN cost-efficient_JJ monitoring_NN of_IN HIV-infected_JJ patients_NNS in_IN large_JJ regional_JJ laboratories_NNS ._SENT (_( Part_NN of_IN this_DT research_NN was_VBD presented_VBN at_IN Monitoring_NP and_CC Diagnostic_NP Tools_NP for_IN the_DT Management_NN of_IN Antiretroviral_JJ Therapy_NN in_IN Resource-Poor_NP Settings_NP ,_, a_DT workshop_NN held_VBN in_IN Bethesda_NP ,_, Md._NP ,_, 11_CD to_TO 13_CD November_NP 2001_CD ,_, and_CC arranged_VBD by_IN Virology_NP Education_NP ,_, B.V._NP ,_, Utrecht_NP ,_, The_DT Netherlands_NP ._SENT )_) FIG._NN 1_CD ._SENT |_SYM Recent_JJ events_NNS leading_VBG to_TO affordable_JJ CD4-T-cell_NN enumeration_NN by_IN flow_NN cytometry_NN ._SENT Recent_JJ events_NNS leading_VBG to_TO affordable_JJ CD4-T-cell_NN enumeration_NN by_IN flow_NN cytometry_NN ._SENT NIBSC_NP ,_, National_NP Institute_NP for_IN Biological_NP Standards_NPS and_CC Control_NP ;_: NEQAS_NP ,_, UK_NP National_NP External_NP Quality_NP Assessment_NP Service_NP ,_, Sheffield_NP ,_, United_NP Kingdom_NP ;_: QASI_NP ,_, Quality_NP Assessment_NP &_CC Standardization_NP for_IN Immunology_NP ,_, Ottawa_NP ,_, Canada_NP ._SENT Clinical_JJ samples_NNS ._SENT |_SYM Samples_NP (_( n_NN =_SYM 93_CD )_) were_VBD received_VBN for_IN routine_JJ immunological_JJ diagnosis_NN at_IN an_DT HIV-immunology_NP laboratory_NN and_CC included_VBD patients_NNS at_IN various_JJ stages_NNS of_IN HIV_NP infection_NN as_IN part_NN of_IN the_DT routine_JJ diagnostic_NN and_CC quality_NN assurance_NN activity_NN at_IN the_DT Royal_NP Free_NP Hospital_NP ._SENT No_DT extra_JJ specimens_NNS from_IN HIV-seropositive_JJ patients_NNS were_VBD required_VBN ._SENT Twelve_CD additional_JJ samples_NNS were_VBD taken_VBN from_IN healthy_JJ volunteers_NNS 21_CD to_TO 59_CD years_NNS of_IN age_NN as_IN approved_VBN by_IN the_DT Institutional_NP Ethics_NP Committee_NP ._SENT These_DT whole-blood_NN samples_NNS were_VBD collected_VBN in_IN EDTA_NP and_CC analyzed_VBD within_IN 24_CD h_NN using_VBG a_DT "_`` lyse-no-wash_NN "_'' procedure_NN ._SENT Briefly_RB ,_, in_IN each_DT tube_NN ,_, 10_CD or_CC 20_CD mul_NN of_IN a_DT diluted_JJ mixture_NN of_IN antibodies_NNS was_VBD admixed_VBN with_IN 50_CD or_CC 100_CD mul_NN of_IN whole_JJ blood_NN ,_, respectively_RB ._SENT After_IN 15_CD min_NN of_IN incubation_NN at_IN room_NN temperature_NN ,_, 2.0_CD ml_NN of_IN lysing_VBG solution_NN (_( 0.17_CD M_NP NH4Cl_NP )_) was_VBD added_VBN ._SENT The_DT samples_NNS were_VBD counted_VBN after_IN a_DT final_JJ 15-min_JJ incubation_NN ._SENT Instrumentation_NN ._SENT |_SYM Absolute_NP lymphocyte_NN subset_NN counting_NN was_VBD performed_VBN on_IN three_CD systems_NNS :_: (_( i_NP )_) a_DT CytoronAbsolute_NP (_( Ortho_NP Diagnostic_NP Systems_NPS Inc._NP ,_, Raritan_NP ,_, N.J._NP )_) operating_VBG with_IN Ortho_NP Trio_NP reagents_NNS and_CC Immunocount_NP II_NP software_NN to_TO provide_VB absolute_JJ counts_NNS by_IN a_DT volumetric_JJ method_NN ;_: (_( ii_NP )_) a_DT FACSCalibur_NP (_( Becton_NP Dickinson_NP Immunocytometry_NP Systems_NP ,_, Oxford_NP ,_, United_NP Kingdom_NP )_) operating_VBG with_IN TruCOUNT_NP tubes_NNS preloaded_VBN with_IN a_DT known_VBN number_NN of_IN beads_NNS (_( 46,295_CD beads_NNS per_IN tube_NN )_) ;_: cell_NN concentrations_NNS were_VBD calculated_VBN with_IN the_DT formula_NN (_( number_NN of_IN events_NNS in_IN the_DT region_NN containing_VBG the_DT cell_NN population/number_NN of_IN events_NNS in_IN the_DT region_NN containing_VBG beads_NNS )_) x_SYM (_( 46,295/test_JJ volume_NN [_SYM i.e._FW ,_, 50_CD mul_NN ]_SYM )_) ;_: and_CC (_( iii_NNS )_) a_DT CytoronAbsolute_JJ system_NN operating_VBG with_IN Immunocount_NP II_NP software_NN using_VBG panleucogating_NN in_IN order_NN to_TO record_VB three_CD parameters_NNS :_: side_NN scatter_NN (_( SSc_NP )_) ,_, green_JJ fluorescence_NN (_( CD45-fluorescein_NP isothiocyanate_NN [_SYM FITC_NP ]_SYM )_) ,_, and_CC orange_JJ fluorescence_NN (_( CD4-phycoerythrin_NP [_SYM PE_NN ]_SYM or_CC CD8-PE_NP )_) ._SENT The_DT volumetric_JJ absolute_JJ counting_NN properties_NNS of_IN the_DT Cytoron_NP were_VBD utilized_VBN with_IN both_DT systems_NNS i_NP and_CC iii_NP ._SENT ._SENT The_DT capacities_NNS of_IN the_DT automatic_JJ biosampler_NN devices_NNS used_VBN were_VBD 100_CD (_( systems_NNS i_NNS and_CC iii_NNS )_) and_CC 40_CD (_( system_NN ii_NN )_) tubes_NNS ._SENT Total_JJ and_CC differential_JJ white_JJ blood_NN cell_NN (_( WBC_NP )_) counting_NN was_VBD performed_VBN on_IN a_DT Bayer_NP 120_CD hematology_NN analyzer_NN in_IN the_DT hospital_NN 's_POS hematology_NN laboratory_NN as_IN part_NN of_IN the_DT routine_JJ service_NN ._SENT Reagents_NNS ._SENT |_SYM During_IN the_DT volumetric-control_NN procedure_NN on_IN the_DT Ortho_NP CytoronAbsolute_NP ,_, Ortho_NP Trio_NP MAbs_NP were_VBD used_VBN ._SENT These_DT included_VBD three_CD tubes_NNS comprising_VBG in_IN tube_NN 1_CD isotype_NN controls_NNS (_( immunoglobulin_NN G1_NP [_SYM IgG1_NP ]_SYM plus_IN IgG2a-FITC-IgG1_NP plus_CC IgG2a-PE-IgG2a-PECy5_NP )_) ,_, in_IN tube_NN 2_CD CD4(OKT4)-FITC-CD8(OKT8)-PE-CD3(OKT3)-PECy5_NN ,_, and_CC in_IN tube_NN 3_CD CD16(3G8)-FITC-CD19(OKB9)-PE-CD3(OKT3)-PECy5_NN (_( original_JJ clone_NN designations_NNS are_VBP shown_VBN in_IN italics_NNS )_) ._SENT During_IN the_DT bead-based_JJ control_NN procedure_NN on_IN the_DT FACSCalibur_NP ,_, TruCOUNT_NP tubes_NNS were_VBD used_VBN in_IN combination_NN with_IN MultiTEST_JJ reagents_NNS (_( Becton_NP Dickinson_NP Immunocytometry_NP Systems_NPS )_) to_TO obtain_VB absolute_JJ CD4_NP counts_NNS ._SENT These_DT included_VBN CD3(SK7)-FITC-CD8(SK1)-PE-CD45(2D1)-PerCP-CD4(SK3)-APC_NP ._SENT The_DT new_JJ CD45-based_JJ protocol_NN was_VBD also_RB based_VBN on_IN the_DT volumetric_JJ procedure_NN performed_VBN on_IN the_DT Ortho_NP Cytoron_NP ._SENT Two_CD tubes_NNS containing_VBG two-color_JJ immunofluorescence_NN (_( IF_IN )_) reagents_NNS were_VBD each_DT tested_VBN ._SENT Tube_NN 1_CD contained_VBN CD45(2D1)-FITC-CD4(RFT4)-PE_NP ,_, and_CC tube_NN 2_CD comprised_VBN CD45(2D1)-FITC-CD8(RFT8)-PE_NP ._SENT These_DT generic_JJ reagents_NNS are_VBP available_JJ in_IN unconjugated_JJ form_NN from_IN the_DT National_NP Institute_NP for_IN Biological_NP Standards_NPS and_CC Control_NP (_( Potters_NP Bar_NP ,_, United_NP Kingdom_NP )_) ._SENT Gating_VBG strategies_NNS for_IN CD4_NP and_CC CD8_NP enumeration_NN ._SENT |_SYM On_IN the_DT Ortho_NP Cytoron_NP ,_, we_PP employed_VBD the_DT Trio_NP reagents_NNS and_CC obtained_VBN absolute_JJ counts_NNS for_IN the_DT following_VBG cell_NN types_NNS :_: T_NN cells_NNS (_( CD3+_NP ;_: low_JJ side_NN scatter_NN )_) ,_, CD4+_NP T_NN lymphocytes_NNS (_( CD3+_NP CD4+_NP CD8-_NP )_) ,_, CD8+_NP T_NN lymphocytes_NNS (_( CD3+_NP CD8+_NP CD4-_NP )_) ,_, B_NP cells_NNS (_( CD19+_NP ;_: low_JJ side_NN scatter_NN )_) ,_, NK_JJ cells_NNS (_( CD3-_NP CD16+_NP )_) ,_, and_CC total_JJ lymphocytes_NNS (_( CD3+_NP T_NN plus_IN CD19+_NP B_NP plus_CC CD16+_NP NK_NP cells_NNS referred_VBD to_TO as_IN Immunosum_NP )_) ._SENT Percentage_NN values_NNS for_IN CD4+_NP T_NN lymphocytes_NNS (_( CD4_NP %_NN )_) were_VBD derived_VBN as_IN the_DT number_NN of_IN CD4+_NP T_NN cells_NNS divided_VBN by_IN the_DT total_JJ number_NN of_IN lymphocytes_NNS based_VBN on_IN the_DT criteria_NNS of_IN CD4+_NP ,_, CD3+_NP ,_, and_CC CD8-_NP cells/Immunosum_NN ._SENT The_DT CD4/CD8_NP ratios_NNS were_VBD calculated_VBN as_IN (_( CD3+_NP CD4+)/(CD3+_NP CD8+_NP )_) values_NNS ._SENT The_DT internal_JJ quality_NN control_NN for_IN pipetting_VBG errors_NNS was_VBD based_VBN on_IN CD3_NP replicates_VBZ using_VBG Immunocount_NP II_NP software_NN :_: samples_NNS for_IN which_WDT the_DT CD3_NP replicates_VBZ differed_VBN from_IN the_DT average_JJ absolute_JJ CD3_NP count_NN by_IN >5_JJ %_NN were_VBD automatically_RB flagged_VBN for_IN further_JJR inspection_NN ._SENT The_DT event_NN threshold_NN was_VBD set_VBN to_TO operate_VB on_IN forward_JJ scatter_NN ._SENT On_IN the_DT FACSCalibur_NP ,_, the_DT gating_VBG strategy_NN recommended_VBN by_IN the_DT manufacturer_NN was_VBD used_VBN ,_, with_IN the_DT threshold_NN set_VBN for_IN red_JJ fluorescence_NN (_( CD45_NP )_) in_IN a_DT single_JJ tube_NN ._SENT For_IN the_DT new_JJ protocol_NN ,_, the_DT gating_VBG strategy_NN was_VBD based_VBN on_IN CD45_NP panleucogating_NN ._SENT A_DT threshold_NN was_VBD first_RB set_VBN for_IN green_JJ (_( CD45_NP )_) fluorescence_NN ,_, and_CC all_DT WBCs_NP were_VBD identified_VBN using_VBG a_DT heterogeneous_JJ CD45/SSc_NP dual-parameter_NN histogram_NN (_( CD45+_NP to_TO CD45+++_NP in_IN gate_NN A_DT )_) ._SENT All_DT WBC_NP events_NNS in_IN gate_NN A_DT were_VBD then_RB sent_VBN to_TO a_DT CD4/SSc_NP histogram_NN ,_, where_WRB CD4_NP T_NN cells_NNS were_VBD counted_VBN (_( CD4++/SSc+_NP in_IN gate_NN E_NN )_) ._SENT The_DT same_JJ gating_VBG strategy_NN was_VBD applied_VBN for_IN CD8_NP counting_VBG in_IN a_DT second_JJ tube_NN ._SENT Here_RB ,_, only_JJ lymphoid_JJ cells_NNS with_IN bright_JJ CD8_NP expression_NN were_VBD counted_VBN as_IN CD8_NP T_NN cells_NNS (_( CD8++/SSc+_NP in_IN gate_NN F_NN ._SENT The_DT CD4/CD8_NP ratios_NNS were_VBD calculated_VBN as_IN (_( CD4++_NP SSc+)/(CD8++_NP SSc+_NP )_) values_NNS ._SENT All_PDT these_DT gating_VBG strategies_NNS were_VBD set_VBN to_TO operate_VB automatically_RB and_CC printed_VBN with_IN all_DT details_NNS ._SENT The_DT internal_JJ quality_NN control_NN for_IN pipetting_VBG errors_NNS was_VBD based_VBN on_IN CD45_NP WBC_NP replicates_VBZ using_VBG the_DT Immunocount_NP II_NP program_NN ._SENT If_IN the_DT CD45_NP total_NN WBC_NP replicates_VBZ differed_VBN from_IN the_DT average_JJ absolute_JJ CD45_NP count_NN by_IN >5_JJ %_NN ,_, the_DT samples_NNS were_VBD flagged_VBN ._SENT All_DT flagged_VBN samples_NNS or_CC those_NNS where_WRB the_DT operator_NN had_VBD detected_VBN gating_VBG irregularities_NNS were_VBD subsequently_RB reanalyzed_VBN ._SENT In_IN the_DT second_JJ stage_NN of_IN the_DT analysis_NN ,_, the_DT different_JJ CD45_NP staining_VBG intensities_NNS among_IN the_DT leukocyte_NN populations_NNS were_VBD used_VBN to_TO identify_VB lymphocytes_NNS (_( CD45+++/SSc+_NP in_IN gate_NN B_NP )_) ,_, monocytes_NNS (_( CD45++/SSc++_NP in_IN gate_NN C_NP )_) ,_, and_CC granulocytes_NNS (_( CD45+/SSc+++_NP in_IN gate_NN D_NP )_) ._SENT Using_VBG absolute_JJ counting_NN and_CC a_DT two-color_NN IF_IN panel_NN in_IN two_CD parallel_JJ tubes_NNS ,_, the_DT following_VBG 15_CD parameters_NNS were_VBD distinguished_VBN and_CC stored_VBN :_: (_( i_NP )_) total_JJ WBC_NP counts_VBZ ,_, (_( ii_NNS )_) absolute_JJ CD4-T-cell_NN counts_VBZ ,_, (_( iii_NP )_) CD4-T-cell_NN percentage_NN among_IN WBC_NP ,_, (_( iv_NP )_) CD4-T-cell_NN percentage_NN among_IN lymphocytes_NNS ,_, (_( v_NN )_) absolute_JJ CD8-T-cell_NN counts_VBZ ,_, (_( vi_NP )_) CD8-T-cell_NN percentage_NN among_IN WBC_NP ,_, (_( vii_NP )_) CD8-T-cell_NN percentage_NN among_IN lymphocytes_NNS ,_, (_( viii_NNS )_) absolute_JJ CD4-_NN plus_CC CD8-T-cell_NN counts_NNS ,_, (_( ix_NNS )_) CD4/CD8_NP ratio_NN ,_, (_( x_LS )_) absolute_JJ lymphocyte_NN counts_VBZ ,_, (_( xi_NN )_) absolute_JJ monocyte_NN counts_VBZ ,_, (_( xii_NP )_) absolute_JJ granulocyte_NN counts_VBZ ,_, (_( xiii_NP )_) lymphocyte_NN percentage_NN among_IN WBC_NP ,_, (_( xiv_NP )_) monocyte_NN percentage_NN among_IN WBC_NP ,_, and_CC (_( xv_NP )_) granulocyte_NN percentage_NN among_IN WBC_NP ._SENT In_IN samples_NNS where_WRB a_DT single_JJ tube_NN was_VBD analyzed_VBN with_IN CD45/CD4_NP ,_, 10_CD parameters_NNS (_( i_NN to_TO iv_NN and_CC x_NN to_TO xv_NP )_) were_VBD recorded_VBN ._SENT Data_NP handling_NN and_CC statistical_JJ analysis_NN ._SENT |_SYM All_DT results_NNS have_VBP been_VBN recorded_VBN in_IN Microsoft_NP Access-based_JJ spreadsheets_NNS ._SENT Following_VBG consultations_NNS with_IN clinicians_NNS ,_, forms_NNS were_VBD created_VBN for_IN reports_NNS ._SENT Depending_VBG on_IN the_DT requests_NNS ,_, these_DT could_MD include_VB the_DT single_JJ parameter_NN of_IN absolute_JJ CD4_NP count_NN or_CC all_DT 10_CD to_TO 15_CD parameters_NNS recorded_VBN above_IN ._SENT After_IN we_PP tested_VBD whether_IN the_DT differences_NNS between_IN the_DT methods_NNS were_VBD normally_RB distributed_VBN ,_, Bland-Altman_NP plots_NNS were_VBD used_VBN to_TO investigate_VB the_DT agreement_NN between_IN the_DT results_NNS obtained_VBN in_IN two_CD different_JJ systems_NNS ,_, such_JJ as_IN the_DT panleucogating_VBG analysis_NN on_IN a_DT volumetric_JJ flow_NN cytometer_NN versus_IN a_DT conventional_JJ "_`` industry-standard_NN "_'' method_NN ._SENT The_DT standard_JJ techniques_NNS included_VBD the_DT volumetric_JJ flow_NN cytometer_NN ,_, CytoronAbsolute_NP ,_, using_VBG the_DT full_JJ Trio_NP panel_NN ,_, as_RB well_RB as_IN the_DT Becton_NP Dickinson_NP FACSCalibur_NP running_VBG the_DT TruCOUNT_NP bead-based_JJ system_NN ._SENT The_DT absolute_JJ CD4+-_NN and_CC CD8+-lymphocyte_NN counts_NNS and_CC the_DT percentages_NNS of_IN these_DT subsets_NNS among_IN leukocytes_NNS and_CC lymphocytes_NNS were_VBD studied_VBN ._SENT Bland-Altman_NP (_( or_CC bias_NN )_) plots_NNS examine_VBP whether_IN two_CD methods_NNS have_VBP sufficient_JJ agreement_NN to_TO be_VB used_VBN interchangeably_RB ._SENT The_DT average_NN of_IN values_NNS obtained_VBN by_IN the_DT two_CD methods_NNS is_VBZ plotted_VBN on_IN the_DT x_NN axis_NN ,_, and_CC the_DT difference_NN between_IN the_DT methods_NNS is_VBZ plotted_VBN on_IN the_DT y_NP axis_NN ._SENT The_DT average_JJ difference_NN between_IN the_DT methods_NNS (_( bias_NN )_) ,_, its_PP$ 95_CD %_NN confidence_NN intervals_NNS ,_, and_CC the_DT limits_NNS of_IN agreement_NN (_( bias_NN +-_NN 2_CD standard_JJ deviations_NNS )_) are_VBP shown_VBN on_IN the_DT plots_NNS ._SENT The_DT Pollock_NP modification_NN is_VBZ identical_JJ to_TO the_DT Bland-Altman_NP analysis_NN except_IN that_WDT the_DT percentage_NN difference_NN is_VBZ expressed_VBN between_IN the_DT compared_VBN methods_NNS ,_, which_WDT is_VBZ best_RBS suited_VBN to_TO illustrate_VB a_DT systematic_JJ bias_NN across_IN a_DT wide_JJ range_NN of_IN absolute_JJ counts_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM CD45/CD4_NP double_VB staining_VBG on_IN blood_NN using_VBG panleucogating_NN with_IN volumetric_JJ absolute_JJ counting_NN ._SENT CD45/CD4_NP double_RB staining_VBG on_IN blood_NN using_VBG panleucogating_NN with_IN volumetric_JJ absolute_JJ counting_NN ._SENT The_DT graph_NN report_NN form_NN is_VBZ printed_VBN to_TO document_VB the_DT autogating_VBG procedure_NN ._SENT First_RB ,_, the_DT CD45_NP side_NN scatter_NN histogram_NN and_CC gate_VB A_DT (_( all_DT leukocytes_NNS )_) are_VBP established_VBN (_( left_VBN )_) ._SENT All_DT events_NNS of_IN gate_NN A_DT are_VBP sent_VBN to_TO the_DT second_JJ display_NN of_IN CD4_NP side_NN scatter_NN (_( right_NN )_) ._SENT The_DT CD4+_NP and_CC lymphoid_JJ cells_NNS (_( in_IN E_NN )_) are_VBP automatically_RB gated_VBN to_TO provide_VB the_DT absolute_JJ CD4-T-cell_NN count_NN ._SENT E/A_NN x_SYM 100_CD is_VBZ the_DT value_NN of_IN the_DT CD4_NP %_NN among_IN all_DT leukocytes_NNS ._SENT The_DT number_NN of_IN events_NNS in_IN gate_NN B_NP (_( absolute_JJ lymphocyte_NN count_NN )_) ,_, gate_NN C_NP (_( absolute_JJ monocyte_NN count_NN )_) ,_, and_CC gate_NN D_NP (_( absolute_JJ granulocyte_NN count_NN )_) are_VBP also_RB defined_VBN ._SENT E/B_NN x_SYM 100_CD is_VBZ the_DT CD4_NP %_NN value_NN among_IN lymphocytes_NNS ._SENT A_DT parallel_JJ tube_NN for_IN CD45/CD8_NP double_JJ staining_VBG can_MD also_RB be_VB run_VBN to_TO provide_VB the_DT total_NN of_IN 15_CD parameters_NNS listed_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT QA_NP ,_, quality_NN assurance_NN ;_: NEQAS_NP ,_, UK_NP National_NP External_NP Quality_NP Assessment_NP Service_NP ._SENT TABLE_NN 1_CD |_SYM Age_NP ,_, sex_NN ,_, and_CC HIV_NP status_NN of_IN patient_JJ population_NN studied_VBD CD4+-T-cell_JJ enumeration_NN using_VBG primary_JJ CD45_NP and_CC CD4_NP gating_VBG ._SENT |_SYM Total_JJ lymphocytes_NNS were_VBD identified_VBN by_IN volumetric_JJ counting_NN (_( i_NP )_) as_IN the_DT sum_NN of_IN T_NN cells_NNS ,_, B_NP cells_NNS ,_, and_CC NK_JJ cells_NNS (_( Immunosum_NP )_) using_VBG Trio_NP MAbs_NP (_( referred_VBN to_TO as_IN a_DT full_JJ Trio_NP panel_NN )_) and_CC (_( ii_NNS )_) as_IN cells_NNS with_IN a_DT bright_JJ CD45_NP expression_NN and_CC lymphoid_JJ side_NN scatter_NN in_IN the_DT CD45-based_JJ protocol_NN ._SENT No_DT significant_JJ systematic_JJ bias_NN was_VBD observed_VBN between_IN the_DT two_CD methods_NNS (_( bias_NN =_SYM -8_CD lymphocytes/mm3_NN )_) ._SENT Next_RB ,_, CD4+-T-lymphocyte_NP counts_NNS were_VBD determined_VBN by_IN the_DT full_JJ Trio_NP panel_NN and_CC the_DT CD45/CD4-based_JJ protocol_NN ,_, i.e._FW ,_, in_IN the_DT presence_NN and_CC absence_NN of_IN a_DT CD3_NP reagent_NN ,_, respectively_RB ._SENT The_DT CD4_NP %_NN values_NNS among_IN lymphocytes_NNS generated_VBN by_IN the_DT two_CD methods_NNS showed_VBD a_DT minimal_JJ bias_NN of_IN +0.38_JJ %_NN (_( in_IN favor_NN of_IN the_DT Trio_NP MAbs_NP )_) ._SENT The_DT absolute_JJ CD4-T-cell_NN counts_NNS yielded_VBD by_IN the_DT two_CD methods_NNS also_RB showed_VBD excellent_JJ agreement_NN (_( bias_NN =_SYM +8_JJ CD4+_NP cells/mm3_NN ;_: limits_NNS of_IN agreement_NN ,_, between_IN -29_CD and_CC +46_JJ CD4_NP cells/mm3_NN )_) ._SENT The_DT agreement_NN between_IN the_DT volumetric_JJ absolute_JJ CD4-T-cell_NN counts_NNS using_VBG CD45/CD4_NP gating_VBG and_CC the_DT bead-based_JJ TruCOUNT_NP tube_NN was_VBD also_RB determined_VBN ._SENT An_DT average_JJ bias_NN of_IN -10_CD CD4_NP cells/mm3_NN was_VBD observed_VBN with_IN widened_VBN limits_NNS of_IN agreement_NN (_( -118_CD and_CC +98_JJ CD4_NP cells/mm3_NN )_) ,_, similar_JJ to_TO the_DT values_NNS previously_RB observed_VBD between_IN the_DT standard_JJ volumetric_JJ and_CC bead-based_JJ single-platform_NN technologies_NNS ._SENT Efficiency_NN of_IN the_DT CD45/CD4_NP gating_VBG protocol_NN on_IN a_DT volumetric_JJ system_NN ._SENT |_SYM After_IN having_VBG documented_VBN CD4_NP enumeration_NN using_VBG a_DT CD45/CD4-based_JJ protocol_NN by_IN volumetric_JJ flow_NN cytometer_NN ,_, we_PP assessed_VBD the_DT sample_NN throughput_NN of_IN the_DT system_NN ._SENT A_DT technician_NN with_IN a_DT month_NN of_IN experience_NN in_IN flow_NN cytometry_NN processed_VBD 100_CD clinical_JJ samples_NNS using_VBG the_DT autobiosampler_NN ._SENT The_DT steps_NNS of_IN the_DT procedure_NN were_VBD monitored_VBN for_IN time_NN ._SENT A_DT batch_NN of_IN 100_CD samples_NNS was_VBD processed_VBN in_IN 95_CD min_NN ._SENT The_DT automated_JJ acquisition_NN on_IN the_DT flow_NN cytometer_NN lasted_VBD for_IN 120_CD min_NN ,_, allowing_VBG the_DT operator_NN a_DT 25-min_JJ break_NN before_IN starting_VBG to_TO prepare_VB the_DT following_VBG batch_NN ._SENT Three_CD batches_NNS of_IN 100_CD samples_NNS could_MD be_VB prepared_VBN within_IN the_DT normal_JJ 8-h_JJ working_NN day_NN ._SENT An_DT additional_JJ batch_NN was_VBD also_RB prepared_VBN at_IN the_DT end_NN of_IN the_DT day_NN for_IN unattended_JJ acquisition_NN during_IN the_DT late_JJ hours_NNS ,_, to_TO be_VB ready_JJ for_IN inspection_NN by_IN the_DT next_JJ morning_NN ._SENT In_IN total_NN ,_, 300_CD to_TO 400_CD clinical_JJ samples_NNS could_MD be_VB processed_VBN each_DT day_NN ._SENT CD8+-T-cell_NN enumeration_NN using_VBG primary_JJ CD45_NP and_CC CD8_NP gating_VBG ._SENT |_SYM We_PP next_RB evaluated_VBD the_DT agreement_NN for_IN CD8_NP enumeration_NN between_IN the_DT CD45-based_JJ protocol_NN and_CC the_DT full_JJ Trio_NP panel_NN ._SENT With_IN the_DT latter_JJ protocol_NN ,_, similar_JJ to_TO the_DT other_JJ currently_RB recommended_VBN protocols_NNS ,_, CD8+_NP T_NN cells_NNS are_VBP counted_VBN when_WRB they_PP coexpress_VBP both_DT CD3_NP and_CC CD8_NP molecules_NNS ._SENT Using_VBG the_DT CD45-based_JJ protocol_NN in_IN the_DT absence_NN of_IN a_DT CD3_NP reagent_NN ,_, a_DT tight_JJ gate_NN was_VBD placed_VBN around_IN lymphoid_JJ cells_NNS with_IN bright_JJ CD8_NP expression_NN (_( median_JJ ,_, 130_CD x_SYM 103_CD antibody_NN binding_JJ capacity_NN per_IN cell_NN )_) ,_, excluding_VBG most_JJS NK_JJ cells_NNS (_( range_NN ,_, 10_CD x_SYM 103_CD to_TO 110_CD x_SYM 103_CD antibody_NN binding_JJ capacity_NN per_IN cell_NN ;_: median_JJ ,_, 24_CD x_SYM 103_CD ABC_NP per_IN cell_NN )_) from_IN the_DT CD8_NP gate_NN ._SENT The_DT correlation_NN was_VBD excellent_JJ throughout_IN the_DT whole_JJ CD8_NP range_NN ,_, but_CC a_DT systematic_JJ bias_NN was_VBD observed_VBN (_( +40_NP CD8_NP T_NN cells/mm3_NN ;_: 95_CD %_NN confidence_NN interval_NN ,_, +32_JJ to_TO +48_NN )_) ,_, representing_VBG +5.2_JJ %_NN of_IN CD8+_NP lymphocytes_NNS ._SENT The_DT CD4/CD8_NP ratios_NNS were_VBD also_RB evaluated_VBN in_IN samples_NNS by_IN the_DT volumetric_JJ method_NN ,_, using_VBG the_DT CD45/CD4_NP and_CC CD45/CD8_NP protocols_NNS in_IN two_CD parallel_JJ tubes_NNS ,_, and_CC compared_VBN to_TO the_DT CD4/CD8_NP ratios_NNS observed_VBD with_IN the_DT full_JJ Trio_NP panel_NN ._SENT The_DT agreements_NNS were_VBD good_JJ with_IN virtually_RB no_DT bias_NN (_( -0.05_CD CD4/CD8_NP ;_: limits_NNS of_IN agreement_NN ,_, between_IN -0.21_CD and_CC +0.12_NP CD4/CD8_NP )_) ._SENT We_PP extended_VBD our_PP$ study_NN to_TO investigate_VB the_DT agreement_NN between_IN the_DT sum_NN of_IN the_DT CD4+_NP and_CC CD8+_NP T_NN cells_NNS generated_VBN with_IN the_DT volumetric_JJ CD45_NP protocol_NN and_CC the_DT T_NN cells_NNS observed_VBD using_VBG CD3_NP staining_VBG in_IN the_DT full_JJ Trio_NP protocol_NN ._SENT The_DT CD45-based_JJ protocol_NN failed_VBD to_TO identify_VB CD3+_NP lymphoid_JJ cells_NNS doubly_RB negative_JJ for_IN CD4_NP and_CC CD8_NP antigens_NNS (_( CD3+_NP CD4-_NP CD8-_NP )_) ._SENT There_EX was_VBD a_DT bias_NN of_IN +125_JJ T_NN cells/mm3_NN in_IN favor_NN of_IN the_DT CD3+-T-cell_NN counts_VBZ recorded_VBN on_IN the_DT full_JJ Trio_NP panel_NN ._SENT These_DT CD3+_NP CD4-_NP CD8-_NP T_NN cells_NNS represented_VBD a_DT 10.1_CD %_NN bias_NN throughout_IN the_DT whole_JJ range_NN of_IN the_DT T-cell_NN counts_VBZ ._SENT WBC_NP subset_NN enumeration_NN using_VBG CD45-based_JJ protocols_NNS on_IN a_DT volumetric_JJ flow_NN cytometer_NN ._SENT |_SYM The_DT expression_NN of_IN CD45_NP antigen_NN is_VBZ the_DT common_JJ feature_NN of_IN all_DT WBCs_NP ,_, and_CC the_DT CD45_NP staining_VBG intensity_NN plus_IN SSc_NP distinguishes_VBZ lymphocytes_NNS ,_, monocytes_NNS ,_, and_CC granulocytes_NNS ._SENT We_PP investigated_VBD the_DT agreement_NN between_IN counts_NNS generated_VBN by_IN this_DT method_NN and_CC those_DT yielded_VBD by_IN a_DT hematology_NN analyzer_NN in_IN the_DT routine_JJ hematology_NN laboratory_NN of_IN our_PP$ institution_NN ._SENT The_DT agreements_NNS for_IN total_JJ WBCs_NP ,_, lymphocytes_NNS ,_, and_CC granulocytes_NNS were_VBD good_JJ ,_, with_IN a_DT minimal_JJ bias_NN of_IN -136_CD WBCs/mm3_NP ,_, -70_CD lymphocytes/mm3_NN ,_, and_CC +78_JJ granulocytes/mm3_NN ._SENT However_RB ,_, the_DT agreement_NN for_IN monocyte_NN enumeration_NN was_VBD poor_JJ ._SENT The_DT hematology_NN analyzer_NN underestimated_VBD the_DT monocyte_NN counts_VBZ with_IN a_DT bias_NN of_IN -179_CD monocytes/mm3_NN ._SENT This_DT is_VBZ a_DT large_JJ value_NN ,_, representing_VBG 35_CD to_TO 40_CD %_NN of_IN the_DT total_JJ monocyte_NN counts_NNS ,_, as_RB already_RB reported_VBN for_IN several_JJ hematology_NN analyzers_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM Bland-Altman_NP plots_NNS to_TO establish_VB the_DT agreements_NNS between_IN the_DT volumetric_JJ CD45/CD4_NP protocol_NN ,_, single_JJ tube_NN ,_, and_CC the_DT "_`` state-of-the-art_JJ "_'' single-platform_NN technology_NN ._SENT Bland-Altman_NN plots_NNS to_TO establish_VB the_DT agreements_NNS between_IN the_DT volumetric_JJ CD45/CD4_NP protocol_NN ,_, single_JJ tube_NN ,_, and_CC the_DT "_`` state-of-the-art_JJ "_'' single-platform_NN technology_NN ._SENT The_DT parameters_NNS studied_VBN were_VBD the_DT total_JJ absolute_JJ lymphocyte_NN counts_NNS (_( a_DT )_) ,_, CD4-T-cell_NN percentage_NN values_NNS among_IN lymphocytes_NNS (_( b_LS )_) ,_, and_CC absolute_JJ CD4-T-cell_NN counts_VBZ (_( c_LS and_CC d_LS )_) ._SENT The_DT standard_JJ technologies_NNS used_VBN were_VBD the_DT full_JJ lymphocyte_NN subset_NN panel_NN (_( three_CD tubes_NNS )_) tested_VBN with_IN the_DT Ortho_NP Trio_NP panel_NN on_IN the_DT CytoronAbsolute_NN (_( a_DT ,_, b_NN ,_, and_CC c_LS )_) and_CC the_DT TruCOUNT_NP bead-based_JJ method_NN (_( one_CD tube_NN )_) performed_VBN on_IN a_DT FACSCalibur_NP (_( d_LS )_) ._SENT FIG._NN 4_CD ._SENT |_SYM Evaluation_NN of_IN the_DT agreement_NN between_IN the_DT volumetric_JJ absolute_JJ CD8-T-cell_NN counts_NNS generated_VBN with_IN the_DT CD45/CD8_NP protocol_NN (_( CD8++_NP SSc+_NP )_) and_CC the_DT full_JJ Trio_NP panel_NN (_( CD3+_NP CD8+_NP )_) ._SENT Evaluation_NN of_IN the_DT agreement_NN between_IN the_DT volumetric_JJ absolute_JJ CD8-T-cell_NN counts_NNS generated_VBN with_IN the_DT CD45/CD8_NP protocol_NN (_( CD8++_NP SSc+_NP )_) and_CC the_DT full_JJ Trio_NP panel_NN (_( CD3+_NP CD8+_NP )_) ._SENT The_DT results_NNS using_VBG linear_JJ regression_NN (_( a_DT )_) and_CC the_DT Bland-Altman_NP plot_NN (_( b_LS )_) and_CC its_PP$ Pollock_NP modification_NN (_( c_LS )_) are_VBP shown_VBN ._SENT In_IN the_DT Pollock_NP modification_NN ,_, the_DT differences_NNS between_IN the_DT two_CD methods_NNS of_IN counting_VBG CD8_NP T_NN cells_NNS were_VBD expressed_VBN as_IN a_DT percentage_NN of_IN the_DT total_JJ CD8_NP counts_VBZ to_TO illustrate_VB the_DT systematic_JJ bias_NN at_IN a_DT 5_CD %_NN level_NN ._SENT FIG._NN 5_CD ._SENT |_SYM Bland-Altman_NP plots_NNS (_( a_DT and_CC b_LS )_) and_CC the_DT Pollock_NP modification_NN (_( c_LS )_) to_TO establish_VB agreements_NNS on_IN the_DT Cytoron_NP between_IN the_DT volumetric_JJ CD45/CD4-plus-CD45/CD8_NP two-tube_NN protocol_NN and_CC the_DT standard_JJ volumetric_JJ method_NN using_VBG Trio_NP reagents_NNS ._SENT Bland-Altman_NP plots_NNS (_( a_DT and_CC b_LS )_) and_CC the_DT Pollock_NP modification_NN (_( c_LS )_) to_TO establish_VB agreements_NNS on_IN the_DT Cytoron_NP between_IN the_DT volumetric_JJ CD45/CD4-plus-CD45/CD8_NP two-tube_NN protocol_NN and_CC the_DT standard_JJ volumetric_JJ method_NN using_VBG Trio_NP reagents_NNS ._SENT The_DT parameters_NNS studied_VBN were_VBD the_DT CD4/CD8_NP ratios_NNS (_( a_DT )_) and_CC the_DT sum_NN of_IN the_DT absolute_JJ CD4-_NN plus_CC CD8-T-cell_NN counts_NNS versus_IN the_DT CD3+-T-cell_NN counts_VBZ (_( b_LS and_CC c_NN ,_, respectively_RB )_) ._SENT In_IN the_DT Pollock_NP modification_NN (_( c_LS )_) ,_, the_DT differences_NNS in_IN total_JJ T-cell_NN counts_NNS were_VBD expressed_VBN as_IN percentages_NNS of_IN T-cell_NN counts_NNS to_TO illustrate_VB the_DT regular_JJ underestimation_NN of_IN total_JJ CD3+-T-cell_NN counts_NNS ,_, at_IN a_DT 10_CD %_NN level_NN ,_, by_IN the_DT CD45_NP protocol_NN ._SENT This_DT bias_NN is_VBZ due_JJ to_TO the_DT existence_NN of_IN CD3+_NP CD4-_NP CD8-_NP T_NN lymphoid_JJ cells_NNS ._SENT TABLE_NN 2_CD |_SYM Timetable_JJ of_IN routine_JJ operation_NN using_VBG a_DT biosampler_NN with_IN a_DT 100-tube_JJ capacity_NN The_DT need_NN to_TO improve_VB laboratory_NN services_NNS for_IN regions_NNS of_IN the_DT world_NN where_WRB the_DT HIV_NP epidemic_NN threatens_VBZ to_TO destroy_VB the_DT fabric_NN of_IN life_NN has_VBZ revitalized_VBN efforts_NNS to_TO identify_VB the_DT most_RBS efficient_JJ techniques_NNS for_IN monitoring_VBG HIV_NP disease_NN ._SENT The_DT present_JJ changes_NNS relate_VBP to_TO the_DT common_JJ areas_NNS of_IN routine_JJ immunology_NN and_CC hematology_NN ,_, such_JJ as_IN quality_NN assurance_NN ,_, sample_NN processing_NN ,_, and_CC transportation_NN ,_, as_RB well_RB as_IN to_TO the_DT challenges_NNS of_IN how_WRB to_TO optimally_RB count_VB blood_NN cells_NNS ._SENT Immunological_JJ methods_NNS ,_, based_VBN on_IN the_DT specificities_NNS and_CC discriminating_VBG capacities_NNS of_IN MAbs_NP ,_, have_VBP recently_RB made_VBN an_DT impact_NN by_IN recognizing_VBG even_RB minor_JJ subsets_NNS of_IN functionally_RB divergent_JJ blood_NN cells_NNS ._SENT By_IN using_VBG flow_NN cytometry_NN ,_, the_DT true_JJ power_NN of_IN directly_RB identifying_VBG cells_NNS by_IN antibodies_NNS ,_, as_RB opposed_VBN to_TO first_JJ investigating_VBG merely_RB their_PP$ morphological_JJ features_NNS ,_, is_VBZ now_RB documented_VBN ,_, and_CC the_DT strategy_NN of_IN primary_JJ immunological_JJ gating_VBG is_VBZ widely_RB used_VBN ._SENT The_DT relevant_JJ examples_NNS include_VBP CD45_NP for_IN leukocytes_NNS and_CC their_PP$ subpopulations_NNS ,_, CD3_NN for_IN T_NN cells_NNS ,_, CD4_NP for_IN the_DT major_JJ T-cell_NN subset_NN and_CC monocytes_NNS ,_, and_CC CD8_NP for_IN the_DT minor_JJ T-cell_NN subset_NN and_CC some_DT NK_JJ cells_NNS ._SENT Reliable_JJ total_JJ lymphocyte_NN counts_NNS have_VBP been_VBN achieved_VBN by_IN the_DT Immunosum_NP technique_NN ,_, providing_VBG the_DT sum_NN of_IN the_DT immunogated_JJ CD3+_NP (_( T_NN )_) ,_, CD19+_NP (_( B_NP )_) ,_, and_CC CD16+_NP (_( NK_NP )_) cells_NNS instead_RB of_IN using_VBG only_RB the_DT lymphocytic_JJ scatter_NN appearance_NN ._SENT The_DT commonly_RB used_VBN display_NN on_IN the_DT cytometers_NNS is_VBZ referred_VBN to_TO as_IN a_DT heterogeneous_JJ ,_, or_CC morphospectral_JJ ,_, protocol_NN to_TO show_VB the_DT IF_IN of_IN cells_NNS stained_VBN with_IN MAb_NP (_( on_IN one_CD axis_NN )_) and_CC the_DT side_NN scatter_NN profile_NN of_IN cells_NNS (_( on_IN the_DT other_JJ axis_NN )_) ._SENT In_IN our_PP$ study_NN ,_, we_PP combined_VBD immunological_JJ CD45_NP gating_VBG with_IN volumetric_JJ absolute_JJ counting_NN on_IN single_JJ platforms_NNS in_IN order_NN to_TO introduce_VB a_DT robust_JJ method_NN for_IN WBC_NP counting_VBG and_CC for_IN enumerating_VBG CD4+_NP and_CC CD8+_NP T_NN cells_NNS ._SENT Our_PP$ four_CD main_JJ findings_NNS are_VBP as_RB follows_VBZ ._SENT First_RB ,_, this_DT study_NN confirms_VBZ our_PP$ previous_JJ work_NN ,_, also_RB performed_VBN on_IN volumetric_JJ flow_NN cytometers_NNS ,_, as_RB to_TO the_DT good_JJ agreement_NN between_IN the_DT absolute_JJ CD4+-T-cells_NP counts_NNS obtained_VBN by_IN direct_JJ CD4_NP gating_VBG and_CC by_IN CD4+_NP CD3+_NP coexpression_NN ._SENT Importantly_RB ,_, however_RB ,_, when_WRB we_PP previously_RB used_VBD CD4_NP MAb_NP on_IN its_PP$ own_JJ without_IN CD45_NP ,_, reliable_JJ CD4%-per-lymphocyte_NN values_NNS could_MD be_VB obtained_VBN only_RB with_IN the_DT constant_JJ vigilance_NN of_IN an_DT experienced_JJ operator_NN ,_, who_WP frequently_RB had_VBD to_TO manually_RB modify_VB the_DT lymphocyte_NN gates_NNS ,_, a_DT time-wasting_NN procedure_NN ._SENT We_PP have_VBP now_RB added_VBN CD45_NN gating_VBG to_TO the_DT protocol_NN and_CC report_VB the_DT excellent_JJ agreement_NN between_IN lymphocyte_NN counts_NNS determined_VBN by_IN CD45-side_NP scatter_NN and_CC by_IN the_DT Immunosum_NP method_NN using_VBG the_DT full_JJ Trio_NP panel_NN ._SENT Thus_RB ,_, CD45_JJ staining_VBG improves_VBZ the_DT efficiency_NN of_IN the_DT new_JJ autogated_JJ protocol_NN ,_, saving_VBG effort_NN and_CC technicians_NNS '_POS time_NN ._SENT Similarly_RB ,_, this_DT gating_VBG strategy_NN shows_VBZ no_DT bias_NN compared_VBN to_TO the_DT bead-based_JJ CD4_NP counts_VBZ but_CC reveals_VBZ occasional_JJ differences_NNS leading_VBG to_TO a_DT wider_JJR spread_NN ._SENT This_DT discrepancy_NN might_MD be_VB a_DT bead-related_JJ phenomenon_NN ,_, because_IN similar_JJ results_NNS are_VBP seen_VBN when_WRB CD4_NP counts_VBZ obtained_VBN by_IN panleucogating_VBG on_IN a_DT double_JJ platform_NN are_VBP compared_VBN to_TO counts_NNS obtained_VBN by_IN the_DT bead-based_JJ method_NN ._SENT The_DT second_JJ conclusion_NN is_VBZ that_IN the_DT CD45/CD4_NP protocol_NN on_IN a_DT volumetric_JJ cytometer_NN provides_VBZ an_DT efficient_JJ system_NN in_IN which_WDT a_DT trained_JJ flow_NN cytometrist_NN can_MD run_VB large_JJ numbers_NNS of_IN tubes_NNS per_IN day_NN (_( >300_JJ samples_NNS using_VBG CD45/CD4_NP alone_RB )_) ._SENT If_IN two_CD parallel_JJ tubes_NNS are_VBP used_VBN with_IN CD45/CD4-_NP and_CC CD45/CD8-double-stained_NP cells_NNS ,_, >150_JJ blood_NN samples_NNS can_MD be_VB studied_VBN ._SENT Obviously_RB ,_, such_JJ intensive_JJ diagnostic_JJ activity_NN needs_VBZ to_TO be_VB supplemented_VBN by_IN clerical_JJ help_NN and_CC supervisory_JJ capacity_NN ._SENT Nevertheless_RB ,_, this_DT capacity_NN illustrates_VBZ the_DT high_JJ efficiency_NN of_IN flow_NN cytometry_NN compared_VBN to_TO that_DT of_IN manual_JJ methods_NNS such_JJ as_IN the_DT Dynabeads_NP system_NN ,_, where_WRB a_DT single_JJ assistant_NN can_MD manually_RB handle_VB only_RB 15_CD to_TO 20_CD samples_NNS per_IN day_NN ._SENT A_DT hugely_RB increased_VBN workload_NN for_IN CD4-T-cell_NN enumeration_NN is_VBZ in_IN line_NN with_IN the_DT expected_VBN demand_NN generated_VBN by_IN the_DT arrival_NN of_IN generic_JJ drugs_NNS for_IN antiretroviral_JJ therapy_NN ._SENT The_DT larger_JJR regional_JJ centers_NNS dedicated_VBN to_TO nationwide_JJ support_NN with_IN organized_JJ sample_NN transportation_NN using_VBG TransFix_NP blood_NN stabilizers_NNS will_MD require_VB this_DT increased_VBN service_NN capacity_NN ._SENT The_DT technical_JJ efficiency_NN of_IN this_DT technology_NN is_VBZ directly_RB related_VBN to_TO three_CD factors_NNS :_: (_( i_NP )_) the_DT fluent_JJ operation_NN with_IN a_DT robust_JJ autogating_NN process_NN ,_, where_WRB only_RB <2_JJ to_TO 4_CD %_NN of_IN samples_NNS need_VBP attention_NN for_IN regating_VBG (_( see_VB above_IN )_) ,_, (_( ii_NNS )_) the_DT use_NN of_IN an_DT efficient_JJ autobiosampler_NN ,_, and_CC (_( iii_NNS )_) a_DT convenient_JJ system_NN using_VBG a_DT Windows_NP environment_NN and_CC a_DT Microsoft_NP Access_NP database_NN for_IN feedback_NN to_TO the_DT clinicians_NNS ._SENT Flexible_JJ reporting_NN ,_, based_VBN on_IN consultation_NN with_IN clinicians_NNS ,_, may_MD include_VB only_RB CD4_JJ counts_NNS or_CC any_DT of_IN the_DT 15_CD parameters_NNS listed_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT The_DT third_JJ finding_NN of_IN our_PP$ study_NN is_VBZ related_VBN to_TO the_DT use_NN of_IN CD3_NP ,_, the_DT specific_JJ T-cell_NN marker_NN ._SENT Arguably_RB ,_, CD3_NP is_VBZ not_RB required_VBN to_TO identify_VB CD4+_NP T_NN cells_NNS ._SENT However_RB ,_, the_DT CD8+-lymphocyte_NP populations_NNS are_VBP more_RBR complex_JJ and_CC display_VB CD8_JJ antigen_NN over_IN a_DT wide_JJ range_NN (_( 15_CD x_SYM 103_CD to_TO 140_CD x_SYM 103_CD CD8_NP molecules/cell_NNS )_) ._SENT The_DT CD8+_NP cells_NNS include_VBP 80_CD to_TO 92_CD %_NN proper_JJ CD8+_NP CD3+_NP T_NN cells_NNS that_WDT display_VBP CD8_NP at_IN a_DT high_JJ level_NN (_( CD8++_NP ;_: 80_CD x_NN 103_CD to_TO 140_CD x_NN 103/cell_NN )_) and_CC 8_CD to_TO 20_CD %_NN CD8+_NP CD3-_NP NK_NP cells_NNS that_WDT express_VBP CD8_NP at_IN a_DT lower_JJR level_NN (_( CD8+_NP ;_: <80_JJ x_NN 103/cell_NN )_) ._SENT It_PP is_VBZ therefore_RB logical_JJ to_TO place_VB a_DT tight_JJ gate_NN around_IN the_DT CD8++_NP population_NN and_CC compare_VB these_DT results_NNS with_IN those_DT obtained_VBN by_IN counting_VBG CD3+-gated_NP CD8_NP T_NN cells_NNS ._SENT The_DT results_NNS described_VBD above_RB show_VB that_IN the_DT CD8++_NP gate_NN underestimates_VBZ CD3+_NP CD8+_NP counts_VBZ by_IN 5.2_CD %_NN ._SENT This_DT bias_NN is_VBZ apparently_RB too_RB modest_JJ to_TO influence_VB the_DT CD4/CD8_NP ratios_NNS (_( bias_NN ,_, -0.05_CD )_) ._SENT An_DT extra_JJ advantage_NN of_IN running_VBG both_DT CD45/CD4_NP and_CC CD45/CD8_NP tubes_NNS is_VBZ the_DT availability_NN of_IN CD4-_NP plus_CC CD8-T-cell_JJ counts_NNS that_WDT disregard_VBP the_DT CD3+_NP CD4-_NP CD8-_NP T_NN cells_NNS ._SENT We_PP have_VBP argued_VBN elsewhere_RB that_IN these_DT double-negative_JJ T_NN cells_NNS represent_VBP a_DT functionally_RB different_JJ ,_, mostly_RB T-cell_NN receptor_NN alphabeta-negative_JJ subset_NN that_WDT should_MD not_RB be_VB included_VBN in_IN the_DT total_JJ T-cell_NN counts_NNS ._SENT Finally_RB ,_, Loken_NP et_FW al._FW have_VBP documented_VBN the_DT differential_JJ expression_NN of_IN CD45_NP antigen_NN on_IN lymphocytes_NNS ,_, granulocytes_NNS ,_, and_CC CD14+_NP monocytes_NNS ._SENT In_IN our_PP$ study_NN ,_, the_DT CD45_NP analysis_NN is_VBZ combined_VBN with_IN volumetric_JJ counting_NN in_IN order_NN to_TO generate_VB absolute_JJ leukocyte_NN differential_NN counts_NNS ._SENT These_DT parameters_NNS ,_, when_WRB defined_VBN on_IN hematological_JJ counters_NNS ,_, can_MD be_VB error_NN prone_JJ ,_, and_CC the_DT monocyte_NN counts_NNS are_VBP frequently_RB underestimated_VBN ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT monocyte_NN counts_VBZ obtained_VBN by_IN CD45_NP gating_VBG and_CC carefully_RB confirmed_VBD by_IN the_DT CD14_NP monocytic_JJ marker_NN expression_NN are_VBP more_RBR accurate_JJ ._SENT Consequently_RB ,_, the_DT methods_NNS described_VBD above_IN ,_, in_IN combination_NN with_IN the_DT use_NN of_IN stabilized_VBN blood_NN preparations_NNS with_IN long_JJ shelf_NN lives_NNS ,_, will_MD assist_VB the_DT establishment_NN of_IN long-awaited_JJ quality_NN assurance_NN schemes_NNS for_IN leukocyte_NN differentials_NNS and_CC absolute_JJ counts_NNS ,_, which_WDT are_VBP required_VBN to_TO coordinate_VB the_DT performance_NN of_IN the_DT wide_JJ variety_NN of_IN different_JJ hematology_NN analyzers_NNS ._SENT In_IN conclusion_NN ,_, the_DT present_JJ volumetric_JJ CD45/CD4_NP flow_NN cytometry_NN ,_, assisted_VBN by_IN more_JJR affordable_JJ sources_NNS of_IN MAbs_NP ,_, has_VBZ wide_JJ applicability_NN in_IN the_DT routine_JJ laboratories_NNS operating_VBG in_IN economy-conscious_JJ environments_NNS ._SENT The_DT specification_NN required_VBN for_IN the_DT two-color_NN IF_IN plus_JJ side_NN scatter_NN used_VBN in_IN this_DT study_NN is_VBZ within_IN the_DT reach_NN of_IN the_DT newly_RB designed_VBN ,_, battery-operated_JJ ,_, smaller-volumetric-flow_JJ cytometers_NNS that_WDT carry_VBP red_JJ diodes_NNS or_CC other_JJ small_JJ light_JJ sources_NNS as_IN the_DT sole_JJ source_NN of_IN light_JJ excitation_NN and_CC are_VBP also_RB capable_JJ of_IN performing_VBG bead-based_JJ enzyme-linked_JJ immunosorbent_JJ assays_NNS with_IN the_DT multiplexing_VBG technology_NN in_IN the_DT area_NN of_IN the_DT differential_JJ diagnosis_NN of_IN infectious_JJ diseases_NNS ._SENT TABLE_NN 3_CD |_SYM Comparative_JJ performances_NNS of_IN a_DT hematology_NN analyzer_NN (_( Bayer_NP 120_CD )_) and_CC the_DT simplified_VBN CD45-based_JJ protocol_NN on_IN the_DT CytoronAbsolute_NN for_IN absolute_JJ WBC_NP enumeration_NN 